Cabozantinib
Sign in to save this workspacePrimary targets: RET, KDR_VEGFR2 · FDA status: FDA Approved
Selectivity scorecard
KISS
92.73
Gini
0.751
CATDS
0.014
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Cabozantinib. Strongest target: DDR2 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | DDR2 | 100.0% | 0.0% |
| 2 | TRKB | 100.0% | 0.0% |
| 3 | DDR1 | 100.0% | 0.0% |
| 4 | HIPK4 | 100.0% | 0.0% |
| 5 | BRK | 99.5% | 0.5% |
| 6 | C_MET | 99.2% | 0.8% |
| 7 | RET | 97.5% | 2.5% |
| 8 | LCK | 97.5% | 2.5% |
| 9 | C_MER | 97.0% | 3.0% |
| 10 | YSK4_MAP3K19 | 96.8% | 3.2% |
| 11 | ROS_ROS1 | 96.0% | 4.0% |
| 12 | AXL | 95.9% | 4.1% |
| 13 | EPHA6 | 95.7% | 4.3% |
| 14 | FLT4_VEGFR3 | 95.2% | 4.8% |
| 15 | KDR_VEGFR2 | 95.0% | 5.0% |
| 16 | FLT3 | 95.0% | 5.0% |
| 17 | RIPK3 | 94.5% | 5.5% |
| 18 | EPHB2 | 94.5% | 5.5% |
| 19 | EPHA4 | 94.5% | 5.5% |
| 20 | LOK_STK10 | 94.3% | 5.7% |
Selectivity landscape
Where Cabozantinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Cabozantinib.
Atlas insights for Cabozantinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 1849.27 | |
| ALLOGRAFT_REJECTION | 6752.63 | |
| ANDROGEN_RESPONSE | 969.71 | |
| ANGIOGENESIS | 1275.34 | |
| APICAL_JUNCTION | 7124.76 | |
| APICAL_SURFACE | 612.34 | |
| APOPTOSIS | 4527.96 | |
| BILE_ACID_METABOLISM | 761.85 | |
| CHOLESTEROL_HOMEOSTASIS | 809.27 | |
| COAGULATION | 863.09 | |
| COMPLEMENT | 3753.94 | |
| DNA_REPAIR | 1118.98 | |
| E2F_TARGETS | 2413.55 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1161.51 | |
| ESTROGEN_RESPONSE_EARLY | 1774.18 | |
| ESTROGEN_RESPONSE_LATE | 1750.44 | |
| FATTY_ACID_METABOLISM | 603.65 | |
| G2M_CHECKPOINT | 2860.62 | |
| GLYCOLYSIS | 1786.54 | |
| HEDGEHOG_SIGNALING | 810.04 | |
| HEME_METABOLISM | 1333.16 | |
| HYPOXIA | 2506.67 | |
| IL2_STAT5_SIGNALING | 1920.39 | |
| IL6_JAK_STAT3_SIGNALING | 3313.71 | |
| INFLAMMATORY_RESPONSE | 2899.84 | |
| INTERFERON_ALPHA_RESPONSE | 476.39 | |
| INTERFERON_GAMMA_RESPONSE | 3743.27 | |
| KRAS_SIGNALING_DN | 360.49 | |
| KRAS_SIGNALING_UP | 2386.31 | |
| MITOTIC_SPINDLE | 4035.29 | |
| MTORC1_SIGNALING | 2448.50 | |
| MYC_TARGETS_V1 | 1926.93 | |
| MYC_TARGETS_V2 | 344.54 | |
| MYOGENESIS | 1657.97 | |
| NOTCH_SIGNALING | 120.32 | |
| OXIDATIVE_PHOSPHORYLATION | 1103.64 | |
| P53_PATHWAY | 2088.73 | |
| PANCREAS_BETA_CELLS | 136.81 | |
| PEROXISOME | 723.94 | |
| PI3K_AKT_MTOR_SIGNALING | 6076.40 | |
| PROTEIN_SECRETION | 1080.14 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 385.18 | |
| SPERMATOGENESIS | 697.18 | |
| TGF_BETA_SIGNALING | 1088.33 | |
| TNFA_SIGNALING_VIA_NFKB | 2578.95 | |
| UNFOLDED_PROTEIN_RESPONSE | 851.70 | |
| UV_RESPONSE_DN | 3031.29 | |
| UV_RESPONSE_UP | 2454.53 | |
| WNT_BETA_CATENIN_SIGNALING | 1103.09 | |
| XENOBIOTIC_METABOLISM | 1141.38 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| SRR23303752 | — | 0.818 |
| EPT0291 | EPN | 0.809 |
| SRR10899984 | — | 0.802 |
| aMVAC.P_005_TURBT_S223 | — | 0.798 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.794 |
Annotations
Sign in to read and post annotations.
Loading…